Study in Adult and Pediatric Patients With HSCT-TMA

Study Identifier:
ALX-TMA-501
ClinicalTrials.gov Identifier:
NCT04970004
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Other

Study Details

Medical Condition
  • Unmapped
Study Drug
    Date
    Jul 2021 - Apr 2022
    Phase 1
    Phase 2
    Phase 3
    Phase 4
    N/A
    Patient Requirements
    Sex: Female & Male
    Age: 1+ years
    Requirements Information
    Sex
    Female & Male
    Age
    1+ years

    Study Details

    Medical Condition
    • Unmapped
    Study Drug
      Date
      Jul 2021 - Apr 2022
      Phase 1
      Phase 2
      Phase 3
      Phase 4
      N/A
      Patient Requirements
      Sex: Female & Male
      Age: 1+ years years
      Requirements Information

      Protocol Summary

      This is an observational, retrospective study designed to assess outcomes in patients diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who were not treated with complement component (C5) inhibitor therapy. Data required to evaluate study outcomes will be abstracted from the medical records of all patients who meet study eligibility criteria.

      Trial Locations

      Location
      Status
      Location
      Clinical Trial Site
      Salt Lake City, Utah, United States, 84112
      Status
      N/A